Kornimate/medical-research-clean huggingface dataset:
the effect of sleep quality on coronary artery disease and in stent restenosis

Conditions: Coronary Artery Disease; In-stent Restenosis

Summary: this is a cross-sectional and follow-up study. we analysis the relationship of sleep quality on coronary artery disease(cad) and in stent restenosis(isr). further, we explore the mechanism of relationship between the sleep quality and cad/ isr by examining the biomarkers in the pathway of sleep-cad/isr.

background: coronary artery disease (cad) is the leading cause of mortality in the world. the important treatment of cad is percutaneous coronary intervention(pci). however, in-stent-restenosis(isr) is the major issue in the pci. the factors of isr include gender, age, diabetes, lipid ,obesity and so on.recently, studies showed that sleep duration and sleep quality have effect on all of factors and have relationship with coronary artery calcification. we like to explore the relationship between sleep quality and cad/isr. aims:this is a cross-sectional and follow-up study. we analysis the relationship of sleep quality on coronary artery disease(cad) and in stent restenosis(isr). further, we explore the mechanism of relationship between the sleep quality and cad/ isr by examining the biomarkers in the pathway of sleep-cad/isr. methods: we include patients who were diagnosed as cad by coronary arteriography. sleep duration and quality were evaluated from sleep questionnaire. during the 6 months and 9-12months, we follow up the patients who got pci and get information of major adverse cardiovascular events (mace) from follow-up questionnaire. on 9-12 months after pci, coronary arteriography were produced in pci patients. biomarkers were tested during the follow-up.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of coronary artery disease * pci patients in the follow-up * written informed consent exclusion criteria: * heart failure; renal failure; secondary hypertension;valvular heart disease ;cancer;

Keywords: sleep duration sleep quality coronary artery disease in stent restenosis
what is the knowledge and use of emergency contraception

Conditions: Abortion

Summary: the main objective is to assess the knowledge of women seeking abortion about emergency contraception. the secondary objectives are to evaluate the use of emergency contraception among women seeking abortion and to identify barriers to the efficacy and use of emergency contraception in these women.


Eligibility criteria:
inclusion criteria: * women aged over eighteen years old * the patient agreed that her questionnaire data should be collected and analyzed for this research. * women who are able to read and write french * woman seeking an abortion at the orthogeny center in university hospitals of strasbourg exclusion criteria: * refusal to participate in the study

Keywords: abortion emergency contraception emergency pill perception of pregnancy risk contraceptive failure
enhancing psychiatric nursing skills in auditory hallucination assessment via ar/vr and virtual osce

Conditions: Randomized Controlled Trial

Summary: the purpose of this study is to develop and evaluate ai-based virtual reality teaching resources aimed at enhancing nursing students' competencies in assessing, communicating with, and managing patients experiencing auditory hallucinations. specifically, this study seeks to improve the ability of nursing students to effectively assess auditory hallucinations, facilitate better communication with patients experiencing such disturbances, and strengthen their skills in managing these symptoms through the implementation of virtual reality-based educational scenarios.

this study employs a quasi-experimental design and uses a convenience sampling method to select senior students from a university nursing program as participants. the study aims to recruit 150 nursing students. the research involves two institutions, with participants being divided into groups within each institution. the students will be randomly assigned by computer into two groups: an experimental group and a control group. the experimental group will receive ar/vr technology-based group training within a virtual clinical environment during their practicum, while the control group will watch educational videos and participate in a general discussion group focused on auditory hallucinations. data will be collected using google forms at two time points: baseline and post-intervention. the research instruments include: 1. a self-assessment questionnaire on confidence in auditory hallucination assessment and intervention; 2. a scale measuring nursing students' knowledge, attitudes, and perceived empathy toward auditory hallucinations; 3. the auditory hallucination situational involvement and empathy scale; 4. an osce (objective structured clinical examination) evaluation form that assesses auditory hallucination assessment skills, empathy toward auditory hallucinations, communication skills, and the ability to manage auditory hallucinations." data will be analyzed using ibm spss 24.0 for descriptive statistics and for comparing outcomes between the experimental group and the control group.

Eligibility criteria:
inclusion criteria: * nursing students who are about to undertake their psychiatry practicum. * those who are willing to join the study and sign the consent form. * those who are willing to bring a smartphone to connect with vr360 and watch the video. * those who are willing to use their smartphone for research purposes (a smartphone will be provided by the research team if needed). exclusion criteria: * individuals with hearing or vision impairments

Keywords: duditory hallucination assessment nurse student ar/vr
topical psoriasis study for patients receiving biologic therapy

Conditions: Psoriasis

Summary: a two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of topicort® bid and 12 weeks bid on two consecutive days a week to patients with ≤5% bsa who are receiving biologic therapy for at least 24 weeks

a two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of topicort® bid and 12 weeks bid on two consecutive days a week to patients with ≤5% bsa who are receiving biologic therapy for at least 24 weeks. adult male and female subjects with moderate to severe chronic plaque psoriasis all patients will receive topicort® bid for 4 weeks. after week 4 patients will receive topicort® bid on two consecutive days a week for 12 weeks.

Eligibility criteria:
inclusion criteria: 1. male or female adults ≥ 18 years of age. 2. diagnosis of chronic plaque-type psoriasis. 3. able to give written informed consent prior to performance of any study related procedures. 4. treated with a biologic agent for a minimum of 24 weeks at baseline. 5. plaque-type psoriasis as defined at screening and baseline by bsa ≤ 5%. 6. females of childbearing potential (fcbp) must have a negative pregnancy test at screening and baseline. fcbp who engage in activity in which conception is possible must use one of the approved contraceptive options: hormonal contraception; intrauterine device (iud); tubal ligation; or partner's vasectomy; male or female condom diaphragm with spermicide, cervical cap with spermicide, or contraceptive sponge with spermicide. 7. subject must be in general good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination. exclusion criteria: 1. \>5% body surface area 2. any condition, which would place the subject at unacceptable risk if he/she were to participate in the study. 3. pregnant or breast feeding, or considering becoming pregnant during the study. 4. malignancy or history of malignancy, except for: 1. treated \[ie, cured\] basal cell or squamous cell in situ skin carcinomas; 2. treated \[ie, cured\] malignancy with no evidence of recurrence within the previous 5 years. 5. use of any investigational drug within 4 weeks prior to randomization, or within 5 pharmacokinetic/pharmacodynamic half lives, if known (whichever is longer). 6. use of oral systemic medications for the treatment of psoriasis within 4 weeks (includes, but not limited to, oral corticosteroids, methotrexate, acitretin, apremilast and cyclosporine). 7. patient used other topical therapies to treat within 2 weeks of the baseline visit (includes, but not limited to, topical corticosteroids, vitamin d analogs, or retinoids). 8. patient received uvb phototherapy within 2 weeks of baseline. 9. patient received puva phototherapy within 4 weeks of baseline. 10. patient has a known hypersensitivity to the excipients of topicort spray® as stated in the label.
an observational study on epithelioid sarcoma

Conditions: Epithelioid Sarcoma

Summary: prospective italian study aimed to provide a description of the population affected by epithelioid sarcoma (es)

the present prospective national study aims to provide a description of the population affected by es, an insight into the natural history of the disease and an answer some on the outstanding questions on its management. also, it will focus on enhancing any differences between the two es variants (classical-type and proximal-type) in order gain a better understanding of the disease, tailor the treatment and lastly improve outcome.

Eligibility criteria:
inclusion criteria 1. histological diagnosis of epithelioid sarcoma according to 2014 world health organization (who) classification, performed on biopsy or surgical specimen 2. signed informed consent 3. adequate patient compliance to treatment or follow up 4. no age limit exclusion criteria 1. other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent 2. impossibility to ensure adequate compliance
study of quetiapine treatment for cannabis dependence

Conditions: Cannabis Dependence

Summary: marijuana is the most commonly used illicit drug in the united states. however, the treatment options for cannabis dependence are limited; notably, no effective pharmacotherapy has been developed. conceptually, the ideal medication treatment for cannabis dependence would: 1. be safe when administered to patients actively using cannabis 2. reduce cannabis intake and promote abstinence 3. treat the symptoms of cannabis withdrawal 4. reduce craving and relapse risk 5. have a low abuse liability.

conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. by antagonizing dopamine, quetiapine may interfere with the reinforcing effects of cannabis, while serotonin type 2a, histamine type 1, and adrenergic receptor antagonism may reduce cannabis withdrawal symptoms, primarily by sedating and anxiolytic effects. the proposed research project is an open-label pilot study to evaluate the tolerability and ideal target dosing range for quetiapine treatment of cannabis dependence over an eight-week period. the purpose of this pilot study is to obtain preliminary data regarding the potential efficacy, tolerability and safety of quetiapine treatment of cannabis dependence before conducting a larger double-blind trial.

Eligibility criteria:
inclusion criteria: 1. between the ages of 18-65 2. meets dsm-iv criteria for current cannabis dependence 3. seeking treatment for cannabis dependence 4. reports using cannabis an average of five days per week over the past 28 days 5. capable of giving informed consent and complying with study procedures exclusion criteria: 1. lifetime history of dsm-iv diagnosis of schizophrenia, schizoaffective disorder, or bipolar disorder 2. current dsm-iv criteria for any other psychiatric disorder that may, according to the investigator's judgment, require either pharmacological or non-pharmacological intervention over the course of the study 3. receiving prescribed psychotropic medication 4. known history of allergy, intolerance, or hypersensitivity to quetiapine 5. pregnancy, lactation, or failure to use adequate contraceptive methods in female patients who are currently engaging in sexual activity with men 6. unstable medical conditions, such as poorly controlled diabetes or hypertension, which might make participation hazardous 7. current dsm-iv diagnosis of substance dependence other than cannabis or nicotine dependence 8. are legally mandated to participate in a substance use disorder treatment program 9. increased risk for suicide 10. diabetes (whether controlled or not), hyperglycemia (fasting glucose \> 100 mg/dl), obesity (bmi \> 30) and elevated lipids (cholesterol \> 200 mg/dl; triglycerides \> 150 mg/dl).

Keywords: cannabis quetiapine
hyaluronic acid in shoulder tendinopathy

Conditions: Shoulder Tendinitis

Summary: multicentric, randomised study to compare the effectiveness on activity pain at 3 months of corticosteroid injection associated with hyaluronic acid with corticosteroids injection alone in patients with tendinopathy of the supraspinatus with clinical reevaluation at one, three and six months.


Eligibility criteria:
inclusion criteria: * active patient aged between 18 and 65; * patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months; * patient with simple tendinopathy or partial tendon rupture; * patient with tendinopathy confirmed by ultrasound or mri; * patient with an active pain visual analog scale ≥ 4 for more than 6 weeks; * patient with an active pain visual analog scale ≥ 4 on the day of inclusion; * patient failing medical treatment (rest, analgesics, nsaids, physiotherapy); * patient able to follow the protocol and having given oral informed consent to take part in the research; * patient affiliated to the social security system or entitled person; exclusion criteria: * patient suffering from a transfixing tendon rupture; * patients suffering from post-traumatic tendon rupture; * patients suffering from calcific tendinopathy (calcification \> 5 mm); * patients with associated glenohumeral osteoarthritis; * patients with associated symptomatic acromioclavicular osteoarthritis; * patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronic inflammatory rheumatism, fibromyalgia, amyloidosis); * patients who have had a subacromial infiltration in the previous 6 months; * patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol); * patients with a known allergy to lidocaine; * patients with a local or generalised infection, or suspected infection; * patients with severe coagulation disorders or taking anticoagulants; * patients with severe and/or uncontrolled hypertension \> 160/100 mmhg; * patients with unbalanced diabetes (last hba1c \> 8.5%); * patients with a history of addiction to psychoactive substances; * patient participating in another clinical research protocol with an impact on the research objectives; * patient already randomised in the study; * patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception\* in the month prior to inclusion and up to 15 days after infiltration; * patients under guardianship, curators or deprived of liberty; * patient under a mandate for future protection activated ; * patient under family guardianship ; * patient under court protection ;

Keywords: shoulder tendinitis hyaluronic acid corticosteroid injection
virtual reality for coping with involuntary early pregnancy loss

Conditions: Early Pregnancy Loss

Summary: this study aims to provide psychological support to women that experienced an early pregnancy loss (when the loss occurs until the 20 weeks of gestation) using an innovative virtual reality prototype and compare the presence and evolution of psychological distress symptoms pre and post-intervention. the main goals of this study are: 1. evaluate the impact of the proposed vr paradigm in women who suffered a gestational loss in the first 20 weeks of gestation, compared to a control group that follows the usual standard care; 2. evaluate the usability, user experience, and acceptance of the proposed approach. participants in the vr group will have an intervention program lasting four weeks, with 3 weekly sessions of 45-60 minutes, using the developed prototype.

early pregnancy loss occurs in about 20% of all pregnancies and can lead to chronic grief and psychological distress symptomatology. although the high prevalence, it is still a very undervalued event, and proper follow-up and psychological guidance are often absent. the present research study aims to evaluate the feasibility of a psychological vr-based approach in a controlled pilot study with 20 women who suffered an early gestational loss in the last 6 months. using the developed prototype, the experimental vr group will have an intervention program lasting four weeks, with 3 weekly sessions of 45-60 minutes. the investigators aimed to verify if the use of the proposed vr paradigm will significantly reduce symptoms of grief, depression, anxiety and post-traumatic stress, and that this reduction will be significantly greater compared to the control group. the study proposed is very innovative in terms of the target population and the use of vr, specifically designed to address gestational loss. in addition, it opens a new avenue of research on a topic that is still silenced and considered taboo in society. thus, this interdisciplinary research has an expected scientific, technological, and social impact, namely: 1) contributes to a better understanding of the process of psychological recovery after an early gestational loss; 2) contributes to the advancement of technologies aimed at psychological support; 3) has the potential to accelerate the resolution of grief by bringing emotional and psychological support to women who do not have access to other means of support; and 4) contributes to reducing the economic burden on health care by providing tools to improve the well-being of patients.

Eligibility criteria:
inclusion criteria: - women that have experienced an involuntary pregnancy loss in the first 20 weeks in the last 6 months; exclusion criteria: * current pregnancy * having a diagnosis of mental disorder, * undergoing any psychological intervention, * vision impairments that could interfere with the execution of the vr tasks.

Keywords: virtual reality psychological intervention personalization
deep learning magnetic resonance imaging radiomic predict platinum-sensitive in patients with epithelial ovarian cancer

Conditions: Predictive Cancer Model

Summary: platinum-sensitive is an important basis for the treatment of recurrent epithelial ovarian cancer (eoc) without effective methods to predict.we aimed to develop and validate the eoc deep learning system to predict the platinum-sensitive of eoc patients through analysis of enhanced magnetic resonance imaging (mri) images before initial treatment.ninety-three eoc patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery from sun yat-sen memorial hospitalin china from january 2011 to january 2020 were enrolled. this deep-learning eoc signature achieved a high predictive power for platinum-sensitive, and the signature based on mri whole volume is better than that on primary tumor area only.


Eligibility criteria:
inclusion criteria: * (1)patients with epithelial ovarian cancer (2 )patients received platinum-based chemotherapy (\>= 4 cycles) and debulking surgery exclusion criteria: * patients with epithelial ovarian cancer received less than 4 cycles platinum-based chemotherapy or no debulking surgery
patient reported outcomes for bladder management strategies in spinal cord injury

Conditions: Neurogenic Bladder; Spinal Cord Injuries; Quality of Life; Incontinence

Summary: the investigators goal is to create a better understanding of patient reported outcomes for bladder management strategies (clean intermittent catheterization (cic), indwelling catheter (idc) and bladder surgery.

our study is a longitudinal observational study between bladder management strategies, comparing outcomes measured by patient reported questionnaires.

Eligibility criteria:
inclusion criteria: * participants with acquired spinal cord injury * participants with neurogenic bladder * participants must be undergoing or starting at least one of the following bladder management treatments at the time of enrollment. a) clean intermittent catheterization (cic) b) have an indwelling catheter (idc) c) spontaneous voiding, and d) have undergone bladder surgery * age 18 or older * willingness and ability to comply with study engagement * able to provide consent exclusion criteria: * degenerative spinal cord issues, such as multiple sclerosis, neuromuscular dysfunction * congenital spinal cord issues, such as spina bifida, myelomeningocele, or cerebral palsy * participants that belong to a vulnerable population (pregnant, prisoners, mentally handicapped, etc) * participants less than 18 years of age

Keywords: urinary bladder neurogenic quality of life spinal cord injury incontinence bladder
clobazam in subjects with lennox-gastaut syndrome

Conditions: Epilepsy; Epilepsy, Generalized; Seizures

Summary: the purpose of this study is to evaluate the safety and efficacy of clobazam as adjunctive therapy in the treatment of seizures which lead to drop attacks (drop seizures) in subjects 2 to 30 years of age with lennox-gastaut syndrome (lgs). subjects will be enrolled at approximately 10 investigational sites in the u.s. for up to 15 weeks. subjects will be randomly assigned to either a low dose or a high dose. the study will include a baseline period, a titration period and a maintenance period. after the maintenance period, subjects will either continue into an open-label extension study or enter the taper period with a final visit 1 week after the last dose.

lgs poses a significant treatment challenge. while antiepileptic medications are the mainstay of treatment, no one antiepileptic drug (aed) provides satisfactory relief for all or most patients with lgs and a combination of treatments is often required. many patients with lgs are refractory to standard aed treatment. more effective and better tolerated treatment options are needed for this population of medically intractable epilepsy patients. clobazam is unique in that it is the only non-1, 4-benzodiazepine used in the treatment of epilepsy.

Eligibility criteria:
key inclusion criteria: * subject must have been \<11 years of age at the onset of lgs * subject must have lgs * subject must be on at least 1 stable dose aed * parent or caregiver must be able to keep an accurate seizure diary key exclusion criteria: * etiology of subject's seizures is a progressive neurologic disease. subjects with tuberous sclerosis will not be excluded from study participation * subject has had an episode of status epilepticus within 12 weeks of baseline * subject has had an anoxic episode requiring resuscitation within 1 year of screening * subject has had a clinically significant history of an allergic reaction or significant sensitivity to benzodiazepines * subject is taking more than 3 concurrent aeds. note: vagal nerve stimulation (vns) or ketogenic diet is allowed and each will be counted as one of the three allowed aeds * if the subject is on the ketogenic diet, has been for less than 4 weeks prior to screening or suffers from frequent stooling * if the subject has a vns, the settings have not been stable for at least 4 weeks prior to screening * subject has taken corticotropins in the 6 months prior to screening * subject is currently taking long-term systemic steroids (excluding inhaled medication for asthma treatment) or any other daily medication known to exacerbate epilepsy. an exception will be made of prophylactic medication, for example, for urinary tract infections or asthma * if the subject is taking felbamate, has been taking it for less than 1 year prior to screening or previous treatment with felbamate resulted in withdrawal due to liver or bone marrow adverse events